A groundbreaking study published in JAMA Psychiatry reveals that small doses of Ozempic (semaglutide) can reduce alcohol cravings and intake among individuals with alcohol use disorder. Conducted over two months with 48 participants, the trial demonstrated that those receiving the medication reported decreased cravings and drinking, compared to the placebo group. Additionally, smokers using Ozempic reduced their smoking frequency. Researchers highlight the potential for microdosing Ozempic to develop new addiction treatments, although further studies are essential to explore dosage and long-term effects.
Ozempic, a weight-loss medication, shows promise in reducing alcohol cravings and smoking addiction, paving the way for novel addiction treatment options.
Collection
[
|
...
]